Arrowhead gains as milestone payments from Sarepta still expected

Arrowhead Pharmaceuticals

23/07/2025 14:06

** Shares of drug developer Arrowhead ARWR.O rise ~4% to $15.50 before the bell

** Company says it still expects $300 million in milestone payments from partner Sarepta Therapeutics SRPT.O by the end of this year

** Sarepta shares down ~2% at $13.40 premarket

** SRPT has not indicated that it does not plan to fulfill its financial obligations, Arrowhead says

** Arrowhead licensed several of its therapies, including four early-stage candidates, to Sarepta as part of an agreement last year

** ARWR received $500 million upfront, and is eligible to receive milestone payments of as much as $10 billion across several therapies from Sarepta

** As of last close, ARWR down 23.4% and SRPT down ~89% YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))